David Luci | President and CEO |
Robert Shawah | Co-Founder and CFO |
Jason McCarthy | Maxim Group |
[Technical Difficulty]
Thank you, Rob and good morning to everyone and thank you for joining us on this morning's conference call to discuss Acurx's Financial Results.
During today's call, we'll review our financial results for the quarter and nine months ended September 30, 2021 as well as some key corporate highlights, and then we'd be pleased to take any questions. In the third quarter, we continued on our critical path forward initiating our Phase 2b be clinical trial of our lead antibiotic candidate, ibezapolstat in patients with C. difficile infection.